Intellectual Property

NeoImmuneTech in-licensed the right of development and commercialization of NT-I7 from Genexine for the territories of North America, Europe and Latin America. NeoImmuneTech and Genexine has been collaboratively establishing a strong intellectual property portfolio of NT-I7 based on a globally proactive patent filing strategy.

  • PCT patents filed for material/formulation/usage
  • hyFc™ platform technology patents have been filed for 13 countries.
    (registered in 11 countries, pending in 2 countries)